Bone Biologics Corp BBLG
We take great care to ensure that the data presented and summarized in this overview for Bone Biologics Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in BBLG
Top Purchases
Top Sells
About BBLG
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
Insider Transactions at BBLG
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Sep 13
2023
|
Deina H Walsh Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
8,000
+34.78%
|
$0
$0.64 P/Share
|
|
Sep 11
2023
|
Jeff Frelick Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
9,500
+35.58%
|
$0
$0.69 P/Share
|
|
Sep 06
2023
|
Deina H Walsh Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
7,000
+49.45%
|
$0
$0.71 P/Share
|
|
Aug 31
2023
|
Jeff Frelick Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
7,600
+49.66%
|
$0
$0.66 P/Share
|
|
Mar 13
2023
|
Don Hankey Chairman of the Board |
SELL
Other acquisition or disposition
|
Indirect |
500,137
-100.0%
|
-
|
|
Oct 15
2021
|
Don Hankey Chairman of the Board |
SELL
Bona fide gift
|
Indirect |
1,004,310
-12.51%
|
-
|
|
Oct 15
2021
|
Don Hankey Chairman of the Board |
BUY
Discretionary transaction
|
Indirect |
476,190
+5.6%
|
$2,380,950
$5.24 P/Share
|
|
Oct 15
2021
|
Don Hankey Chairman of the Board |
SELL
Conversion of derivative security
|
Indirect |
9,361,702
-55.34%
|
-
|
|
Oct 15
2021
|
Don Hankey Chairman of the Board |
BUY
Conversion of derivative security
|
Indirect |
5,928,774
+25.95%
|
$11,857,548
$2.5 P/Share
|